E.P.A. Awards Contracts to U.S. Companies to Screen Chemicals for Human Health Impacts

WASHINGTON- The E.P.A.'s (EPA) ToxCast chemical screening plan has awarded contracts to 4 United States-based companies to test up to 10,000 chemicals for potential toxicity to people and the environment. ToxCast is designed to determine how chemical exposures affect human health. When fully implemented, ToxCast will be able to screen thousands of chemicals in fast, cost-effective tests.

The 4 companies will initially screen up to 1,000 chemicals currently in the ToxCast plan using innovative technologies such as stem cell toxicity tests. These new technologies can quickly determine the potential for a chemical to cause harm to the human body. Screening results from the new technologies will be combined with data already being generated by the other 500 rapid chemical tests used by EPA's ToxCast program.

The chemicals ToxCast is now screening are found in industrial and consumer products, food additives and drugs. ToxCast's goal is to reduce EPA's reliance on slow and expensive animal toxicity tests, enabling the agency to screen chemicals more quickly and to predict and identify potential risks to Americans.

E.P.A. scientific studies using ToxCast have already been published in peer-reviewed science journals, and demonstrate the ability of ToxCast to predict a chemical's potential to cause several diseases.

The 4 companies awarded the contracts have offices throughout the country, and may hire new scientific staff to help with the project. The companies are Vala Sciences, Cee Tox, Life Technologies and BioReliance. 2 of the companies, Vala Sciences and Cee Tox are small businesses based in San Diego, California and Kalamazoo, Mich. All 4 companies may hire new employees as a result of these contracts.

More information on ToxCast: http://epa.gov/ncct/toxcast/
More information on ToxCast database: http://actor.epa.gov/actor/faces/ToxCastDB/Home.jsp

There are currently no comments for this story. Be the first to add a comment!
Click here to add a comment about this story.